Abbott Laboratories (ABT) Cash from Investing Activities (2009 - 2026)

Abbott Laboratories has reported Cash from Investing Activities for 18 years, with the latest figure at -$673.0 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 15.64% year-over-year to -$673.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$22.4 billion (down 790.41% YoY) and the FY2025 annual result came in at -$2.4 billion, down 3.59% from the prior year.
• Cash from Investing Activities climbed to -$673.0 million in Q2 2026 per ABT's latest filing, from -$20.3 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$264.0 million in Q2 2022 and troughed at -$20.3 billion in Q1 2026.
• A 5-year average of -$1.7 billion and a median of -$588.0 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities soared 62.65% in 2024, then plunged 4224.26% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$632.0 million in 2022, then sank by 30.38% to -$824.0 million in 2023, then fell by 5.1% to -$866.0 million in 2024, then retreated by 5.43% to -$913.0 million in 2025, then increased by 26.29% to -$673.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$673.0 million, -$20.3 billion, and -$913.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.